EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Topoisomerase II inhibitors design: Early studies and new perspectives

Hadeer K Swedan, Asmaa E Kassab, Ehab M Gedawy, Salwa E Elmeligie

Bioorganic Chemistry · 2023-07 · 136 · 106548

DOI: 10.1016/j.bioorg.2023.106548 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Bioorganic Chemistry, 2023-07. Verfasst von Hadeer K Swedan und 3 weiteren Autor:innen. Beteiligte Einrichtung: Central Administration of Research and Health Development, Ministry of Health, and Population (MoHP), Cairo P.O. Box 11516, Egypt. Hauptthemen laut MEDLINE: Topoisomerase II Inhibitors, Antineoplastic Agents. Die Arbeit wurde bisher 63-mal zitiert (Crossref) und nennt 154 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The DNA topoisomerase enzymes are widely distributed throughout all spheres of life and are necessary for cell function. Numerous antibacterial and cancer chemotherapeutic drugs target the various topoisomerase enzymes because of their roles in maintaining DNA topology during DNA replication and transcription. Agents derived from natural products, like anthracyclines, epipodophyllotoxins and quinolones, have been widely used to treat a variety of cancers. A very active field of fundamental and clinical research is the selective targeting of topoisomerase II enzymes for cancer treatment. This thematic review summarizes the recent advances in the anticancer activity of the most potent topoisomerase II inhibitors (anthracyclines, epipodophyllotoxins and fluoroquinolones) their modes of action, and structure-activity relationships (SARs) organized chronologically in the last ten years from 2013 to 2023. The review also highlights the mechanism of action and SARs of promising new topoisomerase II inhibitors.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Topoisomerase II InhibitorsAntineoplastic AgentsAntibiotics, AntineoplasticDNA Topoisomerases, Type IIPodophyllotoxinAnthracyclinesTopoisomerase I Inhibitors

Stichwörter der Autor:innen

AnthracyclinesAnticancerEpipodophyllotoxinsFluoroquinolonesMechanism of actionSARTopoisomerase II

Substanzen

Topoisomerase II InhibitorsAntineoplastic AgentsAntibiotics, AntineoplasticDNA Topoisomerases, Type IIPodophyllotoxinAnthracyclinesTopoisomerase I Inhibitors

Autor:innen und Institutionen

  • Central Administration of Research and Health Development, Ministry of Health, and Population (MoHP), Cairo P.O. Box 11516, Egypt.
  • Department of Pharmaceutical Organic Chemistry, Faculty of Pharmacy, Cairo University, Kasr El-Aini Street, Cairo P.O. Box 11562, Egypt. Electronic address: asmaa.kassab@pharma.cu.edu.eg.
  • Department of Pharmaceutical Organic Chemistry, Faculty of Pharmacy, Cairo University, Kasr El-Aini Street, Cairo P.O. Box 11562, Egypt; Department of Pharmaceutical Chemistry, Faculty of Pharmacy and Pharmaceutical Ind…
  • Department of Pharmaceutical Organic Chemistry, Faculty of Pharmacy, Cairo University, Kasr El-Aini Street, Cairo P.O. Box 11562, Egypt.

Zitieren

APA

Swedan, H. K., Kassab, A. E., Gedawy, E. M., & Elmeligie, S. E. (2023). Topoisomerase II inhibitors design: Early studies and new perspectives. Bioorganic Chemistry, 136, 106548. https://doi.org/10.1016/j.bioorg.2023.106548

Vancouver

Swedan HK, Kassab AE, Gedawy EM, Elmeligie SE. Topoisomerase II inhibitors design: Early studies and new perspectives. Bioorganic Chemistry. 2023;136:106548. doi:10.1016/j.bioorg.2023.106548

BibTeX
@article{Swedan2023,
  author = {Swedan, Hadeer K and Kassab, Asmaa E and Gedawy, Ehab M and Elmeligie, Salwa E},
  title = {Topoisomerase II inhibitors design: Early studies and new perspectives},
  journal = {Bioorganic Chemistry},
  year = {2023},
  volume = {136},
  pages = {106548},
  doi = {10.1016/j.bioorg.2023.106548}
}
Kostenlos starten →